Bacteriocin engineering is a key application of synthetic biology at Syngulon. Bacteriocins are genetically encoded antimicrobial peptides whose activity, target spectrum, production and other functional properties can be modified through genetic and molecular engineering. By combining natural bacteriocin diversity with sequence design, DNA synthesis, strain engineering and screening, Syngulon develops new bacteriocin-based functionalities for biotechnology and health.
Engineering Bacteriocin Properties
Synthetic biology enables bacteriocins to be modified to alter properties such as target spectrum, potency, stability and production characteristics. Natural bacteriocins can therefore serve as starting points for engineered variants with characteristics adapted to specific microorganisms and applications.
Designing Bacteriocin Systems
Syngulon also applies synthetic biology to bacteriocin immunity systems, genetic constructs and bacteriocin combinations. These tools support the design of biological systems in which bacteriocins can be produced, deployed or combined in a controlled manner.
From Natural Diversity to PARAGEN
Syngulon’s PARAGEN bacteriocin collection provides a diverse starting point for screening and engineering. Natural bacteriocins can be characterized, modified or combined, while synthetic biology enables the creation of new variants and functionalities adapted to industrial or therapeutic needs.
Applications of Bacteriocin Engineering
Syngulon applies bacteriocin engineering across three core technology areas: antibiotic-free selection for microbial production, precision contamination control in industrial bioprocesses, and therapeutic applications. In each case, synthetic biology provides tools to adapt bacteriocins and their associated genetic systems to the requirements of the target application.
Bacteriocin Production and Screening
Depending on the molecule and development objective, bacteriocins can be produced using in vivo expression, cell-free approaches or chemical synthesis. These production routes can be combined with sequence design and screening to accelerate characterization and optimization of bacteriocin candidates.
Syngulon applies these capabilities both to its internal technology development and to collaborative programs with industrial and research partners. Bacteriocin engineering can be tailored to specific target microorganisms, production environments and application requirements, providing a flexible basis for the development of new industrial and therapeutic solutions.